Esperion Therapeutics (ESPR) EBT Margin (2019 - 2026)

Esperion Therapeutics' EBT Margin history runs 8 years deep, the most recent figure standing at 32.93% for Q1 2026.

• Quarterly EBT Margin rose 3096.0% year-over-year to 32.93% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 2.2% (up 4128.0% YoY) and the FY2025 annual result came in at 5.17%, up 1040.0% from the prior year.
• EBT Margin was 32.93% for Q1 2026 at Esperion Therapeutics, down from 37.16% in the prior quarter.
• Across five years, EBT Margin topped out at 42.29% in Q1 2024 and bottomed at 353.71% in Q2 2022.
• A 5-year average of 129.56% and a median of 63.89% in 2025 frame the typical range for EBT Margin.
• Peak annual rise in EBT Margin reached 83711 bps in 2022, while the deepest fall reached 24628 bps in 2022.
• Esperion Therapeutics' EBT Margin stood at 302.06% in 2022, then soared by 41 bps to 178.06% in 2023, then soared by 76 bps to 42.07% in 2024, then soared by 188 bps to 37.16% in 2025, then tumbled by 189 bps to 32.93% in 2026.
• Business Quant data shows ESPR's EBT Margin at 32.93% in Q1 2026, 37.16% in Q4 2025, and 36.66% in Q3 2025.